Cinryze product monograph
WebAppendix I - Product Monograph Template - Schedule D Page 1 of 39. PRODUCT MONOGRAPH. ... Products made from large pools of human plasma may contain infectious agents, including the causative agents of hepatitis and other viruses that can cause disease. The risk that such products will transmit an infectious agent has been … WebNuwiq Product Monograph Page 3 of 36 Nuwiq® PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Table 1 Product Information Route of administration Dosage form/strength Clinically relevant non-medicinal ingredients Intravenous injection Powder for intravenous injection with 250 IU/500 IU/1000 IU/ 2000 …
Cinryze product monograph
Did you know?
WebZONOVATE® Product Monograph Page 1 of 38 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ZONOVATE® Antihemophilic Factor (Recombinant, B-Domain Truncated) turoctocog alfa Lyophilized Powder 250, 500, 1000, 1500, 2000 and 3000 IU/vial Intravenous injection ATC code: B02BD02 Blood … Web• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. • ADAKVEO is clear to opalescent, colorless or may have a slightly brownish-yellow tint. • Do not use if particles are present in the solution. 4.
WebOctapharma WebOct 10, 2024 · Cinryze : EPAR - Product Information (PDF/409.54 KB) First published: 15/07/2011 Last updated: 10/10/2024 This medicine’s product information is available in all official EU languages. Select ‘available languages’ to access the language you need. Product information documents contain: summary of product characteristics (annex I);
WebOct 19, 2012 · CINRYZE (C1 inhibitor [human]) is a sterile, stable, lyophilized preparation of C1 inhibitor derived from human plasma. CINRYZE is manufactured from large pools of … WebApr 4, 2024 · CINRYZE STN: 125267 Proper Name: C1 Esterase Inhibitor (Human) Tradename: CINRYZE Manufacturer: ViroPharma Biologics LLC Indication: For routine …
WebProducts. The following table provides the prescribing information for Amgen Canada’s major approved products. Due to differences in global labelling, this information is intended for residents of Canada only. Canadian regulations limit the amount and scope of information we can provide on our prescription drugs.
Web1000IUof Cinryze every 3 or 4 days is the recommended starting dose for routine prevention against angioedema attacks;the dosing interval may need to be adjusted according to … campsites in michigan with cabinsWebfull prescribing information warning: severe hypersensitivity reactions, infusion-associated reactions, and risk of acute cardiorespiratory failure in susceptible campsites in minnesota with boat rentalsWebProduct Monograph Master Template Template Date: September 2024 CUVITRU (Normal Immunoglobulin Human) Page 2 of 50 RECENT MAJOR LABEL CHANGES 7 … campsites in mayo irelandWeb7.2 _____ full prescribing information: contents* campsites in moffat scotlandWebOct 10, 2024 · Cinryze : EPAR - Product Information (PDF/409.54 KB) First published: 15/07/2011 Last updated: 10/10/2024 This medicine’s product information is available in … fiservservice servicenowWebAug 11, 2024 · Cinryze (C1 esterase inhibitor [human]) is a prescription drug used to prevent hereditary angioedema (HAE) attacks. Learn about dosage, side effects, and more. campsites in morvichWebSanofi campsites in much wenlock